This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Healthways And Johns Hopkins Medicine Extend And Expand Decade-Long Agreement To Translate Clinical Research Into Practical, Scalable Healthcare Solutions

Healthways (Nasdaq: HWAY) today announced a five-year extension of their decade-long agreement with Johns Hopkins Medicine (JHM) to leverage its clinical, research and educational capabilities in the rapid development, testing and distribution of new well-being improvement science and solutions. Johns Hopkins HealthCare Solutions (JHHCS), a division of Johns Hopkins HealthCare, will coordinate support of the joint effort by faculty and staff members of the institution.

“As a leading provider of health and medical services to the population we serve and as a major employer, Johns Hopkins Medicine faces many of the same challenges confronting healthcare organizations worldwide,” said JHHC President Patricia M. C. Brown, JD. “Successfully meeting these challenges requires new solutions, new distribution and payment models, and new partnerships.”

“Our new agreement with Johns Hopkins reflects a major change in focus for our ongoing collaboration,” noted Ben R. Leedle, Jr., Healthways president and CEO. “Historically, we sought Hopkins’ support to validate our clinical pathways, validate our outcomes and provide support and guidance to our physician outreach efforts. As our relationship matured over the past decade, however, we came to recognize even greater opportunities that could be pursued by harnessing our unique capabilities to contribute to practical research into new approaches that would accelerate our respective abilities to address the health needs of each individual in the populations we serve, rather than just the care needs of those who are already sick.”

The new agreement with JHM reflects Healthways' long-term commitment to developing and distributing programs based on sound clinical research, such as the joint market introduction of Innergy TM, the commercial version of the new standard of care weight-loss program validated by faculty of the Johns Hopkins University School of Medicine in the NIH-supported POWER 1 trial concluded last year.

“We have successfully tested this new model for collaboration through our participation in the POWER trial and the market introduction of Innergy™,” Leedle said. “We now look forward with confidence to the development and distribution of new, even more effective models to engage individuals of all ages in the lifestyle and health behaviors that we know will contribute to their improved well-being, reduced health-related cost and improved performance.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,790.19 +13.76 0.08%
S&P 500 1,979.92 -7.13 -0.36%
NASDAQ 4,748.3610 -32.9030 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs